Triples with object During oral administration of 200 mg or 300 mg twice daily for 14 days in patients at risk of aspergillosis (mainly patients with malignant neoplasms of lymphatic or hematopoietic tissue), the observed pharmacokinetic characteristics were similar to those observed in healthy subjects: Cmax @ 200 mg Oral Q12h(n=9): 3.0mcg/mL Cmax @ 300 mg Oral Q12h(n=9): 4.66mcg/mL 3mcg/mL X 1g/10^6mcg X 1000mL/1L = 0.0003g/L 4.66mcG/mL X 1g/10^6mcg X 1000mL/1L = 0.000466g/L